

March 9, 2016

Maria Rivas, SVP
Merck & Co., Inc.
CRB-210
600 Corporate Drive
Lebanon, NJ 08833
908-236-1120
maria.rivas1@merck.com

NCCN Guidelines Panel: Melanoma

On behalf of Merck & Co., Inc., I respectfully request the NCCN Melanoma Panel to review the enclosed information for KEYTRUDA (pembrolizumab), in reference to NCCN Guidelines for Melanoma.

Specific changes requested:

In section ME-E (page 26), we respectfully request that KEYTRUDA be updated from Category 2A to Category 1 for systemic therapy for patients with metastatic or unresectable melanoma.

FDA approval:

FDA approved KEYTRUDA for the treatment of patients with unresectable or metastatic melanoma on December 18, 2015. Please see enclosed prescribing information (PI).¹

Rationale:

KEYTRUDA received approval by FDA for first-line treatment of patients with unresectable or metastatic melanoma with supporting data included in the PI and based on data from the study KEYNOTE-006 published in the New England Journal of Medicine on April 19, 2015 by Robert *et al.* entitled “Pembrolizumab versus Ipilimumab in Advanced Melanoma”, reporting results from a randomized, controlled, phase 3 study which assessed progression-free survival and overall survival of pembrolizumab (10 mg/kg every 2 weeks or every 3 weeks) versus four doses of ipilimumab at 3 mg/kg every 3 weeks.²

Updated data from the same study (KEYNOTE-006) for progression-free survival, overall response rate and safety data from second interim analysis have also been provided for your review as well as patient-reported outcomes, both presented at Society for Melanoma Research 2015 Congress.^{3,4}

The following resources are submitted to assist the committee with their review:

1. KEYTRUDA (pembrolizumab) prescribing information. Merck & Co., Inc.
2. Robert C *et al.* Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med 2015; 372:2521-32.
3. Schachter J *et al.* Pembrolizumab Versus Ipilimumab in Patients With Ipilimumab-Naive Advanced Melanoma: Updated Efficacy and Safety of the Phase 3 KEYNOTE-006 Study. Poster presented at Society for Melanoma Research (SMR) 2015, November 18-21; San Francisco, California, USA.
4. Petrella T *et al.* Patient-Reported Outcomes in KEYNOTE-006, a Randomized Study of Pembrolizumab Versus Ipilimumab in Patients With Advanced Melanoma. Poster presented at Society for Melanoma Research (SMR) 2015, November 18-21; San Francisco, California, USA.

Thank you for considering this request. Below is my contact information should you need to contact me for additional information.

Sincerely,

A handwritten signature in dark ink, appearing to read "Maria Rivas". The signature is fluid and cursive, with the first name "Maria" and last name "Rivas" clearly distinguishable.

Maria Rivas, SVP
Merck & Co., Inc.
CRB-210
600 Corporate Drive
Lebanon, NJ 08833
908-236-1120
maria.rivas1@merck.com